AMTAS Tablet

1. First line therapy in mild to moderate hypertension

2. Angina pectoris:

a) chronic stable angina

b) vasospastic (Prinzmetal’s or variant) angina.

Dosage and administration:

・Hypertension

Initial dose-5mg once daily

Maximum dose-10mg once daily

・Angina pectoris

Initial dose-5-10mg once daily

・Small fragile, elderly, patients with hepatic insufficiency

Initial dose-2.5mg once daily

In patients with known hypersensitivity to dihydropyridine derivatives.

Usual side effects reported are headache, dizziness, flushing, palpitations, peripheral oedema, fatigue, somnolence and abdominal pain.

Less frequently reported are muscle cramps, dyspnoea, dyspepsia, pruritus and rash.

No significant drug interactions have been reported.

Safety and efficacy of AMTAS during pregnancy and lactation is not established.

In elderly patients and those with liver disease, elimination of amlodipine is significantly reduced and half life is prolonged. In such patients AMTAS should be given with caution with appropriate dose reduction. All calcium channel blockers including AMTAS should be used with caution in patients with heart failure. No dose adjustment is required in patients with renal impairment.

AMTAS selectively inhibits transmembrane influx of calcium ions, with greater selectivity for vascular smooth muscle than for myocardial tissue. This results in vasodilation and in reduction of blood pressure. The decrease in myocardial oxygen requirement along with coronary vasodilation accounts for beneficial effects in myocardial ischaemia.

AMTAS has gradual and sustained onset of action and blood pressure reduction is not associated with reflux tachycardia.

AMTAS has no significant effect on sinus node function or cardiac conduction.

AMTAS is slowly and completely absorbed after oral administration with peak serum (see the package insert about the details.)